---
title: "Inovio Pharma | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286310960.md"
datetime: "2026-05-13T20:17:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286310960.md)
  - [en](https://longbridge.com/en/news/286310960.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286310960.md)
---

# Inovio Pharma | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.28, beating the estimate of USD -0.35.

EBIT: As of FY2026 Q1, the actual value is USD -22.39 M.

#### Revenue

-   Revenue from collaborative arrangement was $0 for the three months ended March 31, 2026, compared to $65,343 for the same period in 2025.

#### Operating Expenses

-   Research and Development (R&D) Expenses decreased to $14,070,107 for the three months ended March 31, 2026, from $16,090,902 for the same period in 2025, primarily due to lower employee and consultant compensation, reduced engineering outside services, and lower expensed inventory.
-   General and Administrative (G&A) Expenses decreased to $7,879,886 for the three months ended March 31, 2026, from $9,024,970 for the same period in 2025.
-   Total Operating Expenses decreased to $21,949,993 for the three months ended March 31, 2026, from $25,115,872 for the same period in 2025.

#### Profitability

-   Loss from Operations was - $21,949,993 for the three months ended March 31, 2026, compared to - $25,050,529 for the same period in 2025.
-   Net Loss was - $19,682,798 for the three months ended March 31, 2026, compared to - $19,694,697 for the same period in 2025.
-   Net Loss per Share (Basic and Diluted) was - $0.28 for the three months ended March 31, 2026, compared to - $0.51 for the same period in 2025.

#### Cash and Investments

-   Cash, Cash Equivalents and Short-term Investments totaled $37.7 million as of March 31, 2026 (excluding net proceeds from the April 2026 offering of $16.0 million), a decrease from $58.5 million as of December 31, 2025.

#### Balance Sheet Highlights

-   Total Current Assets were $39,439,605 as of March 31, 2026, down from $61,123,346 as of December 31, 2025.
-   Total Assets were $49,777,142 as of March 31, 2026, compared to $74,310,035 as of December 31, 2025.
-   Total Current Liabilities were $37,923,025 as of March 31, 2026, compared to $43,668,555 as of December 31, 2025.
-   Total Liabilities were $43,709,260 as of March 31, 2026, compared to $50,213,759 as of December 31, 2025.
-   Total Stockholders’ Equity was $6,067,882 as of March 31, 2026, compared to $24,096,276 as of December 31, 2025.

#### Operational Metrics / Business Highlights

-   The Biologics License Application (BLA) for INO-3107 is under active review by the U.S. Food and Drug Administration (FDA) with a target Prescription Drug User Fee Act (PDUFA) date of October 30, 2026.
-   Inovio Pharmaceuticals, Inc. is advancing commercial readiness plans for INO-3107 in anticipation of a potential approval in 2026 and plans to commercialize it in the U.S. with a contract sales organization.
-   A clinical trial collaboration and supply agreement was announced with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for glioblastoma (GBM).
-   Inovio Pharmaceuticals, Inc. strengthened its balance sheet through an underwritten public equity offering in April 2026, generating approximately $16.0 million in net proceeds.

#### Outlook / Guidance

Inovio Pharmaceuticals, Inc. estimates that its current cash, cash equivalents, and short-term investments will support operations into the first quarter of 2027, extending beyond the target PDUFA date for INO-3107. This projection includes the $16.0 million net proceeds from the April 2026 public offering and an estimated operational net cash burn of approximately $18 million for the second quarter of 2026. These cash runway projections do not account for any potential future capital-raising activities.

### Related Stocks

- [INO.US](https://longbridge.com/en/quote/INO.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)